Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa in adult participants with moderate to severe disease. The study will assess change in disease signs and symptoms.
18 Years and older.
- Diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline.
- Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline, presence of HS
lesions in at least 2 distinct anatomical areas, and draining fistula count of ≤ 20 at
- History of inadequate response or an intolerance to adequate trial of oral antibiotics
for treatment of HS.
- Required to use a daily antiseptic wash on HS lesions.
-History of active skin disease (other than HS) that could interfere with assessment of HS,
including skin infections requiring systemic treatment within 4 weeks of the Baseline